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A novel analog of MDP, the 3’-iodo-4’-azido-L-phenylalanine methyl ester derivative of N-acetyl-L-alanyl- 
D-isoglutamine, has been prepared. This compound is capable of activating macrophages to the tumoricidal 
state and increasing the specific immune response of B cells. It thus appears to exhibit similar biological 
activities to MDP. Moreover, this compound is of potential interest for receptor photolabelling studies. 
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1. INTRODUCTION 
A water-in-oil emulsion of killed mycobacteria 
has been known since the forties to exhibit an im- 
munoadjuvant action. Indeed, ‘Freund’s complete 
adjuvant’, as this preparation is known, is used 
commonly by immunologists to stimulate antibody 
production and induce cellular immunity. It was 
not until the early seventies, however, that the 
minimal chemical structure necessary to reproduce 
the effects of Freund’s adjuvant became defined as 
N-acetyl-muramyl-L-alanyl-D-isoglutamine (I), 
(MDP or muramyl dipeptide) [ 11. 
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MDP has a multiplicity of biologic4 effects 
(review [2]) including potentiation of specific im- 
mune responses, as well as an increase in natural 
resistance to microbial infections and tumor 
development and a more recently described sleep- 
promoting effect [3]. 
More specifically, MDP has been shown to in- 
teract directly with, and elicit biological responses 
from, macrophages and B cells in vitro. For in- 
stance, with macrophages, MDP enhances their 
tumoricidal action [4]. There has been con- 
siderable discussion recently of the possible role(s) 
and location(s) of specific muramyl peptide bind- 
ing receptors on activated macrophages and of 
whether such cell-surface receptors exist [5-71. It 
has been suggested that under some circumstances 
a common set of receptors are shared between 
muramyl peptide and serotonin [8]. With respect 
to B cells, MDP can increase their primary in vitro 
antibody response in appropriate conditions and it 
appears that MDP acts directly on B cells, in a late 
stage of their differentiation to antibody- 
producing cells [9]. To address in molecular detail 
questions such as the location and identity of MDP 
receptor sites (and whether there are several classes 
of these), we have prepared 2 (fig.1). This 
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Fig.1. Structure of MDP and AI-MDP. 
derivative, which is a photolabile analog of 1, was 
designed based on the known structure-activity 
relationships in the MDP family. This derivative, 
the 3’-iodo-4’-azido-L-phenylalanine methyl ester 
analog of MDP (AI-MDP), incorporates an aryl 
azide moiety (from which a highly reactive nitrene 
can be photogenerated) which provides the poten- 
tial to photolabel MDP receptors. We report here 
the biological activities of 2 towards macrophages 
and B cells. 
2. MATERIALS AND METHODS 
2.1. Synthesis 
Derivative 2 was synthesised by isobutylchloro- 
formate-mediated coupling of MDP with 3 ’ -iodo- 
4’-azidophenylalanine methyl ester. The product 
was purified by HPLC using an IBM-controlled 
HPLC system from Gilson or a Waters 600 instru- 
ment and reversed-phase isocratic chromatography 
on a Zorbax CS column (DuPont Instruments) 
(using MeOH/HlO, 60:40 as a solvent system). 
Homogeneity of the sample was tested not only 
by HPLC but also for a range of TLC solvent 
systems. An independent synthesis of 2 by an alter- 
native route gave a product with identical HPLC 
characteristics. The structure and identity of 2 
were confirmed by NMR and elemental analysis. 
Full details of the synthetic and purification pro- 
cedures used will be published elsewhere. For 
biological studies, the freeze-dried compound AI- 
MDP was dissolved in apyrogenic, deionised water 
to provide stock solutions. 
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2.2. Animals 
Female Wistar Albino Glaxo (WAG) rats, 8-10 
weeks old, were obtained from CSEAL (Orleans, 
France) as were 7-12-week-old female BDFl 
(C57B1/6xDBA/2), C57B1/6 and DBA/2 mice. 
2.3. Adjuvant, antigen and medium 
MDP and derivatives were provided by Choay 
Laboratories (Montrouge, France). Sheep ery- 
throcytes were obtained from a selected single 
donor and kindly provided by the CNRZ (INRA, 
Brouessy, France). We used RPMI-1640 (Gibco) 
medium supplemented with 25 mM Hepes, L- 
glutamine, 8% heat-inactivated FCS (Gibco), 
50 PM 2-mercaptoethanol and standard an- 
tibiotics. 
2.4. Preparation of FRM 
BDFl resident peritoneal cells were cultured at 
1 x 106/ml for 90 min and the non-adherent cells 
removed by washing. A further overnight incuba- 
tion was carried out to prepare the supernatant of 
adherent cells which was concentrated IO-fold with 
Immersible-CX (Millipore) and then chromato- 
graphed on Ultrogel AcA54 (IBF). FRM eluted in 
the fraction of apparent molecular mass 35 kDa. 
. 
2.5. Production qf MLC supernatants 
Allogeneic culture supernatants were obtained 
by mixing whole spleen cells from normal DBA/2 
and C57BV6 mice at 10’ cells/ml for 24 h. The 
MLC supernatant contained the complete set of 
helper factors capable of restoring the immune 
responsiveness of B cells [9]: it was used at subop- 
timal doses. 
2.6. Cell preparations 
Macrophages were removed by passage of BDF 1 
splenocytes through Sephadex G-10 columns: this 
preparation is referred to hereafter as G-lo-treated 
cells. To obtain B cells which were depleted of both 
macrophages and T cells, the G-lo-treated cells 
(10’ cells/ml) were incubated with a monoclonal 
F7D5 anti-Thy-l .2 antibody (l/500, Olac, 
Bicester, England) for 30 min at 37°C and then for 
45 min at 37°C with complement (C, l/10). 
2.7. Culture assays 
lo6 splenocytes, G-10 passed cells or purified B 
cells were cultured in flat bottom wells with lo6 
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SRBC (total volume 200~1). The IgM anti-SRBC 
PFC response was determined on day 5. The PFC 
values given are the means of quadruplicate 
cultures. 
2.8. Preparation of alveolar macrophages 
Macrophages were lavaged from the lungs of 
rats with normal saline as described [lo]. The 
resulting cell suspension in MEM containing 5% 
FCS (endotoxin-free) was supplemented with an- 
tibiotics. Cells (lo5 or 2 x lo5 in 0.25 ml) were in- 
troduced into the wells of 96-well plates (Falcon 
Plastics, Oxnard, CA). Macrophages were allowed 
to adhere for 3-4 h, and then washed twice with 
PBS. 
2.9. Tumor cells 
The P77 syngeneic tumor line used was cloned 
from a lung fibrohistocytoma radioinduced in 
WAG rats [11,12]. 
2.10. Cytotoxicity assay 
This was a modification of a previously de- 
scribed method [ 131 in which the cumulative incor- 
poration of [3H]thymidine into tumor cell DNA 
over a 20 h period was measured. Tumor target 
cells (2.5 x 104, P77) were added to each well in 
MEM containing 10% FCS, antibiotics, 
[3H]thymidine (28 Ci/mmol, CEA, Saclay, 
France) mixed with unlabelled thymidine to give a 
final thymidine concentration of 1.2 PM and a 
specific activity of 1 Ci/mmol. The medium was 
supplemented with 20 ng/ml of LPS (Difco) unless 
otherwise stated. After 20 h incubation at 37°C 
with 5% COz, the radioactivity incorporated was 
collected on glass fiber filters in a cell harvester 
(Skatron, Norway) and counted in a p-scintillation 
spectrometer (LKB). 
Tumor cells were also cultivated in the absence 
of macrophages under similar conditions. The 
validity of this assay, in which incorporation of 
[3H]thymidine is directly proportional to the in- 
crease in the number of viable tumor cells, has 
been demonstrated [ 141. 
3. RESULTS AND DISCUSSION 
The new derivative of MDP, AI-MDP (2), was 
synthesised by an unequivocal route (see section 2). 
A prerequisite for the use of derivative 2 as analog 
of MDP is to demonstrate the existence and nature 
of its biological activity relative to that of MDP. In 
this work, studies are reported to exemplify the ac- 
tivity of AI-MDP (2) in the immune system with 
both nonspecific resistance (in macrophages) and 
specific immunity (in B cells). We shall deal first 
with the results of macrophage studies. 
3.1. Activation of macrophages towards tumor 
cytotoxicity by MDP and AI-MDP 
Unlike mouse peritoneal macrophages, rat 
alveolar macrophages respond both well and 
reproducibly to MDP, and consequently were used 
in this work [4]. Rat alveolar macrophages in- 







Fig.2. Rat alveolar macrophages were incubated at 8 x 
lO-r/ml in 96-well plates with muramyl peptides at 
various concentrations in MEM medium supplemented 
with 5% FCS (LPS-free) and 20 ng/ml added LPS. 
After 24 h, the macrophages were washed and lo5 P77 
target cells were added in the presence of [3H]thymidine 
for 20 h. Incorporation of label into tumor cell DNA 
was measured as described in section 2 and the results 
are expressed as percentage growth inhibition (070 GI): 
% GI = 100 (1 - “,, 
where X is the incorporation into the DNA of tumor 
cells cultured with treated macrophages and R the 
incorporation into tumor cells cocultured with 
macrophages exposed to medium only. The latter value 
was always 80% or more of the incorporation into 
tumor cells cultured alone, thus the macrophages were 
not intrinsically cytotoxic. % GI values given are means 
of results from quadruplicate cultures. MDP (0); AI- 
MDP (0); MDP(D,D) (0). 
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to inhibit the growth of syngeneic P77 tumor cells 
at an effector: target ratio of 8, provided that a 
suboptimal amount of LPS (20 ng/ml), which is 
inactive per se, was present during induction of 
cytotoxicity, as reported for MDP [IO]. Typical 
results are shown in fig.2. Similar results were ob- 
tained at an effector: target ratio of 4 except that 
the maximum percentage of growth inhibition 
reached in the presence of AI-MDP was 78% (cf. 
94% obtained for fig.2). Clearly, under these con- 
ditions AI-MDP is effective in stimulating tumor 
growth inhibition by the macrophages. 
tagonists at 10m6 to 2.5 x lo-’ M) were also com- 
pletely inactive. This behaviour contrasts with 
recent results [8] describing serotonin as active in 
inducing Oi-/Hz02 generation by macrophages. 
On detailed analysis these results are not conflict- 
ing if we take into account the fact that Oi-/H202 
generation by macrophages is a good marker of the 
primed state of macrophages, but not of the ac- 
tivated antitumor state [ 151. 
3.2. Specific antibody response of B cells 
stimulated by MDP and AI-A4DP 
From fig.2 it can be seen that the activating ef- The effects of MDP and AI-MDP on the specific 
fect of muramyl peptides is dose-dependent, the in vitro immune response to SRBC are summarized 
half-effective concentration being in the range in fig.3. The results of fig.3A show that the in- 
IO-*-lo-’ M for MDP and in the range lo-“-5 x crease of the PFC response, the so-called adjuvant 
10e9 M for AI-MDP, depending on the particular effect, is dose-dependent and increases up to a con- 
macrophage preparation used. Thus, it appears centration of about 10m6 M. The lower values ob- 
that AI-MDP is one to two orders of magnitude tained at higher concentrations are caused by the 
more potent than MDP itself in this bioassay. In stimulation of suppressor cells which has been 
these studies MDP-D,D (the stereoisomer of MDP shown to occur at high concentrations of MDP 
with D- in place of L-alanine) was completely in- [16]. The optimum increase of the PFC response 
capable of activating rat alveolar macrophages for induced by AI-MDP is obtained at a much lower 
tumor cytotoxicity. Serotonin (lo-’ to 1O-5 M), concentration. On the basis of fig.3A, AI-MDP is 
methylsergide and ketanserin (serotonin an- at least one order of magnitude stronger at increas- 
o- 
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Fig.3. Effect of various doses of MDP and AI-MDP on the in vitro immune response to SRBC as measured by the 
number of PFC at day 5. Spleen cells (A), macrophage-depleted spleen cells (B) and B cells (C) were cultured at lo6 
cells/200~1 well with 5 x lo5 SRBC, in the absence or presence of either FRM (B) or MLC supernatants (C). Values 
represent the mean of results from quadruplicate wells. MDP (O,O) or AI-MDP (0, n ) were added to cultures in the 
absence (0, q ) or presence (0, H) of either FRM (B) or MLC supernatants (C). Control cultures for (A) whole spleen 
cells (A); (B) GlO-passed cells with (A) or without (A) FRM; (C) B cells with (A) or without (A) MLC supernatant. 
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ing antibody production in spleen cells than MDP (M.C.) and to NATO for travel funds allowing the 
itself. Moreover, the dose-response curves for both reality of a bench-level collaboration in this dif- 
MDP and AI-MDP are qualitatively similar, ficult area. We thank Dr D. Verge for the generous 
possibly indicating parallel behaviour. gift of ketanserin and methylsergide. 
Fig.3B summarises the results obtained with 
MDP and AI-MDP with respect to the specific im- 
mune response to SRBC of macrophage-depleted 
spleen cells (i.e. GlO-treated cells, see section 2) 
and of B cells (i.e. spleen cells stripped of their 
macrophage and T cell components). The 
GlO-treated cells do not respond to SRBC (with or 
without muramyl peptide adjuvant) unless sup- 
plied with a monokine, in this case FRM which is 
produced spontaneously by unstimulated macro- 
phages [17]. Relative to FRM, MDP and AI-MDP 
increase the PFC value about 2-fold but there ap- 
pears to be no significant difference in effectivity 
of MDP and AI-MDP in the stimulation of 
macrophage-depleted cells. 
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